Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Therapy of travelers' diarrhea with rifaximin on various continents
American Journal of Gastroenterology, Volume 98, No. 5, Year 2003
Notification
URL copied to clipboard!
Description
OBJECTIVE: Our aim was to compare the efficacy and safety of rifaximin, a virtually nonabsorbed antibiotic, 600 and 1200 mg per day, with placebo in patients with travelers' diarrhea. METHODS: This was a multicenter, 1:1:1 randomized, parallel-group, double-blind study, conducted in Antigua, Guatemala; Guadalajara and Morelia, Mexico; and the coast of Kenya north and south of Mombasa. Adult patients with acute travelers' diarrhea were recruited; exclusion criteria included primarily medication that could influence the outcome. Subjects were treated for 3 days, three times daily; follow-up lasted 5 days. For each 24-h period, the subjects completed a diary card. Pre- and posttreatment stool, blood, and urine samples were assessed. RESULTS: Among the 380 volunteers, median time to the last unformed stool was 32.5 and 32.9 h in both rifaximin groups, compared with 60.0 h with placebo (p = 0.0001). Also, secondary clinical outcome measures were favorably influenced by the active agent. No relevant side effects were reported. CONCLUSION: Rifaximin is efficacious and safe for treatment of travelers' diarrhea at daily doses of 600 mg or higher. © 2003 by Am. Coll. of Gastroenterology.
Authors & Co-Authors
Steffen, Robert
Switzerland, Zurich
Universität Zürich
Sack, David Allen
Unknown Affiliation
Jiang, Zhidong
Unknown Affiliation
Lowe, Brett S.
Unknown Affiliation
Waiyaki, Peter G.
Unknown Affiliation
DuPont, Herbert L.
Unknown Affiliation
Statistics
Citations: 152
Authors: 6
Affiliations: 1
Identifiers
Doi:
10.1111/j.1572-0241.2003.07283.x
ISSN:
00029270
Research Areas
Disability
Study Design
Cohort Study
Study Locations
Kenya